Treatment of non-small cell lung cancer (NSCLC).
| Τίτλος | Treatment of non-small cell lung cancer (NSCLC). |
| Publication Type | Journal Article |
| Year of Publication | 2013 |
| Authors | Zarogoulidis, K., Zarogoulidis P., Darwiche K., Boutsikou E., Machairiotis N., Tsakiridis K., Katsikogiannis N., Kougioumtzi I., Karapantzos I., Huang H., & Spyratos D. |
| Journal | J Thorac Dis |
| Volume | 5 Suppl 4 |
| Pagination | S389-96 |
| Date Published | 2013 Sep |
| ISSN | 2072-1439 |
| Abstract | Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Additionally radiotherapy should be offered in patients with N2 lymph nodes. In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3(rd) generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug. |
| DOI | 10.3978/j.issn.2072-1439.2013.07.10 |
| Alternate Journal | J Thorac Dis |
| PubMed ID | 24102012 |
| PubMed Central ID | PMC3791496 |
